Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes, with focus on wound care and surgical procedures. Products are used by surgeons and medical personnel to help over 65 million patients in over 90 countries world-wide. Mölnlycke’s ambition is to make the lives of patients better.

Mölnlycke, headquartered in Gothenburg, Sweden, is a world-leading specialist provider and innovator of single-use wound care and surgical products. It has a long history of challenging the status quo and, through innovation, create advanced wound care products that reduce the healing time and suffering of patients. This approach has made Mölnlycke the market leader within advanced wound care dressings. In addition, Mölnlycke is a pioneer in the field of dressings and other products for the prevention of wounds, such as pressure ulcers. Mölnlycke also makes the operating room more efficient with innovative and safe surgical solutions. Cutting-edge and cost-efficient products have made Mölnlycke the company it is today.

Over the years the entrepreneurial and innovative spirit that characterizes Mölnlycke has resulted in an R&D-department that is committed to bringing new, innovative products to the market. Also, demographic factors, such as an aging population and an increase in surgical procedures, have created a greater demand for high-quality medical products. This has in turn resulted in growth and improvements further reinforcing our offering to the market. Mölnlycke has grown strongly since it was acquired over the years. Successful acquisitions have also been made to complement the product offering.



In 2021, Mölnlycke reorganised into four business areas focused on meeting customer needs. Wound Care, Operating Room Solutions, Gloves and Antiseptics now have end-to-end responsibilities for their business.

Mölnlycke’s strategic approach is built on customer insights and sets out a new direction that will take us to 2025. We have identified customer centricity, digitalisation and sustainability as our three corporate strategic priorities.

Mölnlycke successfully launched Avance Solo, a battery-powered negative pressure wound therapy (NPWT) system in 2021. Avance Solo is a breakthrough for patients who need NPWT, giving them more mobility and freedom while managing exudate effectively and supporting healing.

Click here for Mölnlycke's website

Mölnlycke -  Key facts

EUR m.









Number of employees



Patricia Industries ownership (capital/votes): 99/99  |  Initial investment year: 2007 (sole owner 2010)